SHIRE PLC: Transaction in Own Shares

Transaction in Own Shares 
September 20, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")
announces that, in accordance with the authority granted by shareholders at the
Company's Annual General Meeting on April 30, 2013, it purchased 3,896 of its
ordinary shares of 5 pence each ("Ordinary Shares") on September 19, 2013
through both direct purchases of Ordinary Shares, and through the purchase of
Ordinary Shares underlying ADRs. The highest and lowest price paid for the
directly acquired Ordinary Shares was 2548.00 pence per share and 2535.00 pence
per share respectively, and for those Ordinary Shares acquired though the
purchase of ADRs was 4091.33 cents per share and 4078.67 cents per share
The purchased shares will be held as treasury shares. Following the above
purchase, the Company holds 9,723,202 Ordinary Shares as treasury shares and
has 553,174,161 Ordinary Shares in issue (excluding treasury shares). 
The purchases were made by an independent third party which makes its trading
decisions independently of, and uninfluenced by, the Company. The independence
of the third party enables the Company to continue to purchase Ordinary Shares
(including Ordinary Shares underlying ADRs) during close periods and other
prohibited periods, should they arise. The third party has been appointed by
the Company to make purchases to December 31, 2013. 
For further information please contact: 
Investor Relations                                                              
Eric Rojas                         +1 781 482 0999    
Sarah Elton-Farr               +44 1256 894157    
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing treatments
for symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas. 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
-0- Sep/20/2013 06:00 GMT
Press spacebar to pause and continue. Press esc to stop.